RxDoctor Payments Data

Christina Bright, MD

Rheumatology · Bend, ORNPI 1063684934

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 80.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $102 and has fallen 86.7% since, to $14 in 2025. That places this record below the midpoint for rheumatology clinicians in OR, where the typical reported total is $253.

$157in general payments, 2019–2025

Across 5 payments — averaging $31.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$127
  • AstraZeneca$17
  • Pfizer$13

What the payments were for

  • Food & beverage$14492%
  • Education$138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen3$127
AstraZeneca1$17
Pfizer1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157 in reported general payments places this provider in the 40th percentile of 79 rheumatology providers in Oregon.

See all rheumatology providers in Oregon

Medicare billing

Part B allowed, 2024
$2,640,148
Medicare patients
959
Services billed
157,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab91$672,858
Enbrel SureclickEtanercept75$566,079
EnbrelEtanercept54$420,396
Cosentyx Sensoready (2 Pens)Secukinumab39$283,323
Skyrizi PenRisankizumab-Rzaa12$247,735
Cimzia (2 Pack)Certolizumab Pegol24$182,727
Actemra ActpenTocilizumab34$116,372
Cosentyx (2 Syringes)Secukinumab16$115,860
Taltz AutoinjectorIxekizumab11$74,785
TymlosAbaloparatide26$68,914
BenlystaBelimumab12$57,874
KevzaraSarilumab11$51,176
Leflunomide233$17,563
Hydroxychloroquine Sulfate407$16,515
Hadlima(Cf) PushtouchAdalimumab-Bwwd13$13,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$127$420,39654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 rheumatology providers in Oregon.

Other rheumatology in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →